Collectively, these findings identify NOP56 as an oncogenic driver that promotes CRC progression by inducing p53 degradation, whereas its inhibition triggers apoptosis via p53 acetylation regulated by the SIRT1/p300 axis, highlighting NOP56 as a promising therapeutic target for p53 wild-type CRC. This evidence concerns the gene SIRT1 and colorectal carcinoma.